To inquire about opportunities for collaboration with Merrimack, please contact:
One Kendall Square
Building 700, Suite B7201
Cambridge, MA 02139
In September 2014, we entered into an ex-U.S. focused collaboration with Baxter (now Baxalta) for the development and commercialization of ONIVYDE® (irinotecan liposome injection),* also known as MM-398 or nal-IRI. Through this collaboration, Baxalta has exclusive development and commercialization rights for all potential indications of ONIVYDE outside the United States and Taiwan, and Merrimack retains commercialization rights in the United States; the rights in Taiwan are held separately.
In May 2011, we entered into an agreement with PharmaEngine to consolidate the worldwide development and commercialization rights to ONIVYDE, with PharmaEngine retaining commercialization rights in Taiwan.
In November 2013, we entered into an agreement with Actavis (now Allergan) where Merrimack will utilize its proprietary nanoliposomal technology platform to develop and manufacture various pharmaceutical products for Actavis to commercialize around the world. We will produce bulk drug product at our Cambridge, MA nanoliposomal manufacturing facility.
Cancer Treatment Centers of America®
In June 2012, we established a broad partnership with Cancer Treatment Centers of America® (CTCA) to advance the goal of being able to provide individualized treatment solutions to cancer patients. This collaboration encompasses research on diagnostics using our network signaling approach to analyze patients' tumors as well as clinical trial research. As part of the collaboration, CTCA will contribute archived tumor biopsies from its extensive tumor databank as well as prospectively collected tumor samples, and Merrimack will utilize its Systems Biology approach to identify the network signaling that drives cancer growth.
*Click here for full Prescribing Information, including Boxed WARNING.